ANNX Company Profile and Key Details

Q: Who are the executives of ANNX?

Dr. Ted Yednock Ph.D.Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory BoardHenk-Andre Kroon M.D.Senior Vice President of Translational MedicineMr. Douglas Love J.D., Esq.Chief Executive Officer, Pres & DirectorDr. Larry C. Mattheakis Ph.D.Executive Vice President & Chief Scientific OfficerMr. Michael Overdorf M.B.A.Executive Vice President & Chief Bus. OfficerMiriam MasonSenior Vice President of Corporation CommunicationsMs. Jennifer LewExecutive Vice President, Chief Financial Officer & Corporation Sec.Mr. Douglas Love Esq., J.D.Chief Executive Officer, Pres & DirectorDr. Dean R. Artis Ph.D.Chief Scientific Officer & Executive Vice PresidentDr. Jamie Dananberg M.D.Chief Medical OfficerMirella Villa Del ToroSec.

NASDAQ : ANNX

Annexon

$5.07

-0.12-2.31%

Open: 3:17 PM

59.21

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Annexon, Inc. (ANNX) stock declined over -2.31%, trading at $5.07 on NASDAQ, down from the previous close of $5.19. The stock opened at $5.32, fluctuating between $5.04 and $5.32 in the recent session.

Stock Snapshot

5.19

Prev. Close

606.35M

Market Cap

5.04

Day Low

-3.6

P/E Ratio

-1.41

EPS (TTM)

-1.55

Cash Flow per Share

5.32

Open

119.6M

Number of Shares

5.32

Day High

81.05%

Free Float in %

3.2

Book Value

1.43M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 22, 2025	5.18	5.48	5.11	5.19	2.39M
Dec 19, 2025	4.86	5.42	4.85	5.17	10.25M
Dec 17, 2025	4.82	4.97	4.81	4.90	1.8M
Dec 16, 2025	4.91	5.01	4.75	4.80	2.28M
Dec 15, 2025	4.99	5.07	4.80	4.91	3.34M
Dec 12, 2025	5.03	5.34	4.95	4.97	5.45M
Dec 11, 2025	4.91	5.13	4.89	5.04	3.36M
Dec 10, 2025	4.85	5.00	4.84	4.90	1.64M
Dec 09, 2025	4.87	4.98	4.79	4.86	2.25M
Dec 08, 2025	4.72	5.00	4.71	4.86	2.38M
Dec 05, 2025	4.48	4.74	4.48	4.61	1.89M
Dec 04, 2025	4.45	4.55	4.25	4.49	2.37M
Dec 03, 2025	4.10	4.31	4.08	4.28	1.74M
Dec 02, 2025	4.25	4.44	4.01	4.06	4.13M
Dec 01, 2025	4.42	4.50	4.07	4.13	2.22M
Nov 28, 2025	4.36	4.64	4.35	4.50	1.76M
Nov 26, 2025	4.41	4.45	4.26	4.32	3M
Nov 25, 2025	4.53	4.60	4.33	4.44	2.83M
Nov 24, 2025	4.45	4.70	4.37	4.51	3.82M
Nov 21, 2025	4.29	4.42	4.17	4.27	3.81M

Contact Details

Brisbane, CA 94005

United States

https://www.annexonbio.com 650 822 5500

About Company

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barr� syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Stock Peers

ARGX

-2.95-0.35%

argenx SE$852.04 REGN

11.4+1.48%

Regeneron Pharmaceuticals, Inc.$779.36 MDGL

11.81+2.00%

Madrigal Pharmaceuticals, Inc.$602.83 UTHR

-3.34-0.65%

United Therapeutics Corporation$513.79 VRTX

4.11+0.90%

Vertex Pharmaceuticals Incorporated$460.31 ALNY

7.5+1.87%

Alnylam Pharmaceuticals, Inc.$407.73 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

7.48+2.74%

Praxis Precision Medicines, Inc.$280.40 KRYS

8.81+3.66%

Krystal Biotech, Inc.$249.61 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Annexon, Inc. (NASDAQ:ANNX) closed at $5.07 USD, losing -$0.12 (-2.31%) from the previous close of $5.19. The stock is currently mid-range between its 52-week high and low $1.28 and $5.66. With a market capitalization of about $606.35 million, Annexon, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.21). Key stats such as the average daily volume over the past year has been around 2.73 million shares, volume is running light vs its 52-week average. Headquartered in Brisbane, CA, Annexon, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Douglas E. Love, the company employs approximately 106 people and listed since July 24, 2020. Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.

Technical Performance

ANNX has shown sold momentum, gaining 4.43% over the past week and 74.16% over the past quarter, though year-to-date performance is up 1.17%. Short-term trend indicators are bearishly aligned (SMA20 10.71%, SMA50 37.23%, SMA200 93.31%). The stock’s 14-day RSI is 70.56 (overbought), while the ATR of 0.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -8.3% below its high and over 303.89% above its low. Average 10-day trading volume of 4.01 million shares is significantly above the 3-month average of 2.66 million, indicating heightened recent market interest.

Valuation Metrics

Annexon, Inc. trades at a P/E ratio of -4.17, slightly below the S&P 500 average, with a price-to-sales ratio of 184.62 and a price-to-book ratio of 3.92 trading at moderately above to book value. The P/FCF stands at -4.02, also below market averages.

Dividend & Fair Value

Annexon, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.15. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Annexon, Inc. generated EPS of -$1.41 over the past year. Five-year average earnings growth is -0.09%. Wall Street analysts project EPS growth of 5.95% annually over the next five years. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.32. Next year's EPS is expected at $3.74. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $14.00. The high target offers 420.23% upside. The low target suggests 169.75% downside. The mean target is $18.00. This offers 246.82% upside. Annexon, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 8.82%. The prior quarter beat by -5.56%. Over the last six quarters, Apple has recorded several small beats. These include -99.9% in August 12, 2024.

Shareholding & Insider Activity

Annexon, Inc. has 149.06 million shares outstanding. The public float is 111.26 million shares, elevated short interest at 8.26% of float. This equals 10.50 million shares. The short ratio is 3.42 days. Institutional investors hold 100.5% of the float. Insiders own 0.42%. Satter Muneer A holds 9.73 million shares, Bain Capital Life Sciences Investors, LLC has 5.70 million shares and Clarus Lifesciences III, L.P. has 2.73 million shares. Over the past six months, insider transactions show net buying. They sold 3.09 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Annexon has not generated any revenue. Returns are negative, with ROA at -45.10% and ROE at -53.58%.
On valuation metrics, Annexon trades at a P/E of -4.17, P/S of 184.62 and P/B of 3.92. The current ratio is 5.67 and quick ratio is 5.67. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1569.45 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.14, supported by a cash flow-to-debt ratio of -5.65.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Annexon posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $3.27M (margin 0.00%). Operating income was - $143.72M (margin 0.0%). Net income was- $134.24M (EPS - $1.77).
The company ended the quarter with $259.72M in cash and short-term investments, a total debt of $31.36M, and net debt of - $193.76M. Total assets were $297.67M, with equity of $250.56M. Financials further reflected weakness, with operating cash flow of - $121.14M, free cash flow of - $121.34M, and capital expenditures of - $193.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Annexon, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.45%, with price expected at $5.94 by January 05, 2026, within a range of $5.54 to $6.37 3-Month Outlook: Projected rise of 70.71%, reaching $8.86 by March 20, 2026, with a range of $8.43 to $9.34. 1-Year Outlook: Projected gain of 484.2%, with price at $30.32 by December 22, 2026, within a range of $24.21 to $40.83.

Key Takeaways

Annexon, Inc. (NASDAQ:ANNX) shares are flat 1.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Annexon, Inc. trading at a premium to the broader market with a P/E of -4.17. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.54, suggesting 315.03% upside. Our AI forecast model points to short-term strength (14.45% over two weeks), a medium-term rise (70.71% over three months), and a longer-term gain (484.2% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Annexon, Inc. (ANNX) stock price?

Annexon, Inc. (NASDAQ: ANNX) stock price is $5.07 in the last trading session. During the trading session, ANNX stock reached the peak price of $5.32 while $5.04 was the lowest point it dropped to. The percentage change in ANNX stock occurred in the recent session was -2.31% while the dollar amount for the price change in ANNX stock was - $0.12.

ANNX's industry and sector of operation?

The NASDAQ listed ANNX is part of Biotechnology industry that operates in the broader Healthcare sector. Annexon, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ANNX?

Dr. Ted Yednock Ph.D.
Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
Henk-Andre Kroon M.D.
Senior Vice President of Translational Medicine
Mr. Douglas Love J.D., Esq.
Chief Executive Officer, Pres & Director
Dr. Larry C. Mattheakis Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Michael Overdorf M.B.A.
Executive Vice President & Chief Bus. Officer
Miriam Mason
Senior Vice President of Corporation Communications
Ms. Jennifer Lew
Executive Vice President, Chief Financial Officer & Corporation Sec.
Mr. Douglas Love Esq., J.D.
Chief Executive Officer, Pres & Director
Dr. Dean R. Artis Ph.D.
Chief Scientific Officer & Executive Vice President
Dr. Jamie Dananberg M.D.
Chief Medical Officer
Mirella Villa Del Toro
Sec.

How ANNX did perform over past 52-week?

ANNX's closing price is 303.89% higher than its 52-week low of $1.29 where as its distance from 52-week high of $5.66 is -8.3%.

How many employees does ANNX have?

Number of ANNX employees currently stands at 106.

Link for ANNX official website?

Official Website of ANNX is: https://www.annexonbio.com

How do I contact ANNX?

ANNX could be contacted at phone 650 822 5500 and can also be accessed through its website. ANNX operates from 1400 Sierra Point Parkway, Brisbane, CA 94005, United States.

How many shares of ANNX are traded daily?

ANNX stock volume for the day was 1.43M shares. The average number of ANNX shares traded daily for last 3 months was 2.73M.

What is the market cap of ANNX currently?

The market value of ANNX currently stands at $606.35M with its latest stock price at $5.07 and 119.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	106
Beta	1.21
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ANNX Company Profile and Key Details

Annexon

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Valuation Metrics